Business Description
Grace Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : CA00430K4028
Share Class Description:
FRA:L8S: Ordinary SharesTotal Employee Number:
6Description
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.96 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 35 | |||||
3-Year EPS without NRI Growth Rate | 36.2 | |||||
3-Year FCF Growth Rate | 37 | |||||
3-Year Book Growth Rate | -24.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.1 | |||||
Quick Ratio | 8.1 | |||||
Cash Ratio | 7.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -12.11 | |||||
ROA % | -11.34 | |||||
ROIC % | -18.45 | |||||
3-Year ROIIC % | -915.42 | |||||
ROC (Joel Greenblatt) % | -92316.67 | |||||
ROCE % | -16.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.61 | |||||
Price-to-Tangible-Book | 2.7 | |||||
EV-to-EBIT | -2.07 | |||||
EV-to-EBITDA | -2.07 | |||||
EV-to-Forward-Revenue | 14.79 | |||||
EV-to-FCF | -2.58 | |||||
| Price-to-Net-Current-Asset-Value | 2.7 | |||||
| Price-to-Net-Cash | 2.75 | |||||
Earnings Yield (Greenblatt) % | -48.31 | |||||
FCF Yield % | -22.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grace Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.405 | ||
| Beta | -0.4058 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 2.78 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.78 - 2.78 | ||
| Shares Outstanding (Mil) | 16.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grace Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grace Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-13 | In 123 days | ||
| First quarter earnings results for 2027 | 2026-08-12 | In 30 days | ||
| Annual report for 2026 | 2026-06-18 | 2.78 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-18 | 2.78 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 10:30 | 2.78 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-02-12 | 2.78 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2025-11-13 | 2.78 (+0.00%) | ||
| General meeting for 2025 | 2025-09-12 08:30 | 2.78 (+0.00%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 | 2.78 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-08-12 | 2.78 (+0.00%) |
Show
Entries
Grace Therapeutics Inc Frequently Asked Questions
What is Grace Therapeutics Inc(FRA:L8S)'s stock price today?
The current price of FRA:L8S is €2.78. The 52 week high of FRA:L8S is €2.78 and 52 week low is €2.78.
When is next earnings date of Grace Therapeutics Inc(FRA:L8S)?
The next earnings date of Grace Therapeutics Inc(FRA:L8S) is 2026-08-12 Est..
Does Grace Therapeutics Inc(FRA:L8S) pay dividends? If so, how much?
Grace Therapeutics Inc(FRA:L8S) does not pay dividend.
Press Release
Articles on Grace Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers